Ownership Summary
Xilio Therapeutics, Inc. (NASDAQ:XLO) has 37 institutional investors that have filed 13F reports for the period ending December 2025.
- They owned 27.6% of outstanding stock in December 2025, up from 15.2% the prior quarter.
- Their total shares held in XLO increased 102.61% quarter over quarter, and separately, investors owning Xilio Therapeutics increased 5.71% from a year ago.
- Among the 37 funds, 16 bought more Xilio Therapeutics shares, 5 sold down, and 16 held their ground.
- Institutional investors collectively held 39.73Mn shares in Xilio Therapeutics as of December 2025, up by 20.12Mn shares quarter on quarter, and up 12.77Mn shares year over year.
- As of December 31, 2025, the biggest holder of Xilio Therapeutics is Gilead Sciences, Inc. at 650.39K shares, representing 0.45% of shares outstanding.
- Leading sellers of Xilio Therapeutics shares for the quarter ending December 2025 were Gilead Sciences, Inc. (0).
- According to Business Quant data, leading holders of XLO for December 2025 are Gilead Sciences, Inc. (650.39K).